3-[(2S,4S)-4-Mercaptopyrrolidine-2-Carboxamido]Benzoic Acid Hcl

Production-scale handling of 3-[(2S,4S)-4-mercaptopyrrolidine-2-carboxamido]benzoic acid hydrochloride—an enantiomerically pure thiol-bearing chiral building block—requires rigorous exclusion of atmospheric oxygen during storage and transfer. Stainless steel 316L vessels purged with nitrogen at 0.5–1.0 bar overpressure are employed to prevent disulfide dimer formation, a degradation pathway detectable by RP-HPLC at retention time shifts exceeding 0.3 min relative to the monomer standard. The compound’s free thiol exhibits pKₐ ~8.3, necessitating buffering at pH 5.5–6.5 during aqueous-phase reactions to suppress thiolate-mediated racemization at the C-2 stereocenter of the pyrrolidine ring. Bulk shipments typically involve double-bagged foil laminate packaging with desiccant inserts, maintaining headspace moisture below 100 ppm H₂O, validated against USP〈921〉Method Ic.

Carbapenem β-Lactam Core Construction via C-2 Side Chain Acylation

The compound functions as a protected mercaptopyrrolidine donor in the assembly of the trans-configured hydroxyethyl side chain characteristic of carbapenem antibiotics including meropenem and doripenem. In the commercial synthesis of meropenem trihydrate, the hydrochloride salt is neutralized in situ with N-methylmorpholine in anhydrous dimethylacetamide at −15 to −20°C, then coupled to the activated p-nitrobenzyl ester of the carbapenem bicyclic nucleus using a mixed anhydride generated from pivaloyl chloride. The thiol group remains unprotected during this step—a deliberate process decision exploiting the steric shielding provided by the cis-relationship between the C-4 mercapto and C-2 carboxamido substituents. Acylation selectivity exceeding 98.5% at the pyrrolidine nitrogen over the thiol sulfur is confirmed by ¹H-NMR integration of the C-3 methine proton of the pyrrolidine ring, monitored at δ 4.2–4.4 ppm.

Industry compliance standard: ICH Q7 GMP for Active Pharmaceutical Ingredients, Section 8.3 (Critical Process Parameters); residual solvent analysis per USP〈467〉, with DMAc limit set at ≤1090 ppm. Formulation addition ratio: The hydrochloride is charged at 1.05–1.15 molar equivalents relative to the β-lactam nucleus, the slight excess compensating for competing hydrolysis of the mixed anhydride intermediate under the cryogenic coupling conditions. Downstream manufacturing process: Post-coupling, the reaction mass is quenched with aqueous KH₂PO₄ buffer (pH 6.8) and extracted with ethyl acetate; the organic layer undergoes palladium-on-carbon (5% Pd/C, Type 487) hydrogenolysis at 2.5–3.0 bar H₂ to cleave the p-nitrobenzyl protecting group, monitored for endpoint by TLC (silica gel 60 F₂₅₄, ethyl acetate:methanol 9:1). Terminal product type: Meropenem trihydrate, USP Reference Standard lot-certified, milled to particle size D₉₀ ≤ 30 µm for intravenous formulation.

Process deviation analysis from multi-tonne campaigns identifies the exotherm during pivaloyl chloride addition as the critical control point. Adiabatic calorimetry (ARC) data indicate an onset temperature for the mixed anhydride decomposition at −5°C, mandating jacket temperature setpoints of −25°C for reactors exceeding 5000 L working volume. Extended holding of the acylated intermediate prior to hydrogenolysis—beyond 8 hours at 2–8°C—results in gradual thiolactone formation via intramolecular displacement, quantified by a characteristic carbonyl absorbance shift from 1680 cm⁻¹ to 1745 cm⁻¹ in FT-IR. This impurity, if not controlled below 0.15 area%, co-crystallizes with meropenem trihydrate in subsequent acetone-water recrystallization and compromises polymorphic purity as determined by XRPD against reference pattern JCPDS 00-058-1927.

What governs the selection of the hydrochloride salt rather than the zwitterionic free base in commercial carbapenem acylation? The hydrochloride form suppresses nucleophilic interference from the pyrrolidine nitrogen during mixed anhydride activation. Thermogravimetric analysis of the hydrochloride salt shows a single mass loss event at 218–224°C corresponding to HCl evolution and simultaneous ring degradation, whereas the free base exhibits a broad decomposition profile initiating at 147°C, incompatible with the thermal demands of continuous-flow processing equipment operating at Steady-State jacket temperatures of −10°C to 25°C during coupling and workup. The hydrochloride’s solubility profile—freely soluble in DMAc and DMF (> 200 mg/mL at 20°C), sparingly soluble in acetonitrile (8–12 mg/mL)—allows precipitation-driven purification through anti-solvent addition without thermal concentration, preserving optical purity measured at enantiomeric excess ≥ 99.5% by chiral HPLC (Chiralpak AD-H, hexane:ethanol:trifluoroacetic acid 80:20:0.1).

When aqueous-phase peptide conjugation replaces organic-phase acylation, the mercaptopyrrolidine’s reactivity is leveraged through thiol-maleimide click chemistry.

Buffer selection at pH 6.5–7.0 using sodium phosphate (50 mM) with EDTA (1 mM) maintains thiol nucleophilicity while chelating trace metal ions that catalyze aerobic oxidation to disulfide. The maleimide-functionalized peptide—typically a 6–12 residue sequence terminating in Ahx-maleimide—is reacted with 1.2–1.5 equivalents of the mercaptopyrrolidine hydrochloride in degassed buffer under continuous argon sparge. Reaction completion at 23 ± 2°C is confirmed by Ellman’s reagent (DTNB) assay, with residual free thiol concentration dropping below 0.5% of initial value within 45 minutes. Compliance: ICH M7(R2) for mutagenic impurity control, with maleimide residual limit set at ≤1.5 µg/day based on TTC of 1.5 µg/day for unknown mutagens. Addition ratio: The compound is used stoichiometrically at 1.0–1.3 molar equivalents to peptide maleimide. Manufacturing: AKTA Pure chromatography with Superdex 30 Increase 10/300 GL column for conjugate purification, monitoring at 214 nm and 280 nm dual wavelength. Product: Antibody-drug conjugate (ADC) linker-payload intermediates destined for cathepsin B-cleavable dipeptide constructs.

Enzymatic Resolution Monitoring: Chiral Discrimination at C-2 and C-4 Stereocenters

The (2S,4S) stereochemistry defines biological target affinity in dipeptidyl peptidase-4 (DPP-4) inhibitor pharmacophores modeled on the pyrrolidine-2-carbonitrile scaffold. During the chemoenzymatic synthesis of vildagliptin analogues, the mercaptopyrrolidine benzoic acid derivative is employed as an internal standard in chiral HPLC method validation for monitoring enzymatic racemization at the C-2 position. The analytical method employs a Chiralpak IC-3 column (4.6 × 250 mm, 3 µm) with n-hexane:2-propanol:diethylamine (65:35:0.1) mobile phase at 1.0 mL/min, resolving the (2S,4S) enantiomer from its (2R,4R) antipode with resolution factor Rs ≥ 2.5. Limit of detection for the undesired enantiomer is 0.05% w/w, critical for satisfying ICH Q6A enantiomeric impurity thresholds for active substances with a single chiral center controlling pharmacophore geometry.

Industry standard: ICH Q2(R2) Validation of Analytical Procedures, specificity and linearity parameters verified across range 0.05–5.0% of the undesired enantiomer; FDA Guidance for Industry: Development of New Stereoisomeric Drugs. Addition ratio in analytical protocols: The compound serves as a 1.0 mg/mL stock solution in methanol, diluted to 50 µg/mL working concentration for injection; not a reactant but a calibration standard, used at 0.01–0.1% relative to test sample mass. Manufacturing context: The compound is synthesized via lipase-catalyzed kinetic resolution of racemic N-carbobenzoxy-4-mercaptopyrrolidine-2-carboxylic acid, using Candida antarctica lipase B immobilized on acrylic resin (Novozym 435) at 40°C in tert-butyl methyl ether saturated with water (0.5% v/v). Product: Reference standard-grade material with Certificate of Analysis documenting chiral purity ≥ 99.8%, assigned against USP Reference Standard via qNMR using dimethyl sulfone as internal calibrant.

Crystallization-induced diastereomeric resolution introduces an alternative production pathway wherein the hydrochloride is treated with (+)-di-p-toluoyl-D-tartaric acid in isopropanol:water (90:10) at reflux. The resulting diastereomeric salt precipitates with de exceeding 97% after a single crystallization cycle; a second recrystallization from acetonitrile:isopropanol (70:30) raises de to ≥ 99.5%. This classical resolution avoids the thermal lability concerns associated with preparative chiral SMB (simulated moving bed) chromatography operated at 35–40°C, where prolonged residence time on chiral stationary phase leads to thiol oxidation detectable by a yellow discoloration (absorbance at 405 nm exceeding 0.15 AU in 10 mg/mL solution).

How do particle engineering and salt-form manipulation affect dissolution rate in biorelevant media for oral solid dosage applications? A spray-dried dispersion of the hydrochloride salt with hydroxypropyl methylcellulose acetate succinate (HPMCAS-MG grade) in acetone:water (80:20), processed on a Büchi B-290 mini spray dryer with inlet temperature 120°C and outlet temperature 58–62°C, generates amorphous solid dispersion particles with D₅₀ 4–6 µm. Fasted-state simulated intestinal fluid (FaSSIF, pH 6.5) dissolution testing in USP Apparatus 2 at 75 rpm shows 85% release within 30 minutes, versus 18% for the crystalline hydrochloride of equivalent particle size. Stability of the amorphous form under ICH conditions (40°C/75% RH, open dish) requires confirmation of glass transition temperature (Tg) via modulated DSC; polymer miscibility assessed by single-Tg criterion at 118 ± 3°C indicates adequate amorphous solid dispersion quality for 6-month storage without crystallization as determined by absence of birefringence under polarized light microscopy at 100× magnification.

Peptide coupling reagent screening for solution-phase amide bond formation with the benzoic acid carboxyl group of the compound has identified HATU and HBTU as comparable activators, diverging only in racemization extent at the pyrrolidine C-2 position.

DIC/Oxyma demonstrates the lowest C-2 epimerization risk while maintaining high coupling efficiency; however, the reagent combination is incompatible with substrates containing free carboxylic acids unprotected at the benzoic acid position unless the mercaptopyrrolidine amine is first Boc-protected. In the absence of N-protection, Oxyma can acylate the pyrrolidine nitrogen, generating an N-hydroxyguanidino impurity isolated by preparative HPLC and characterized by HRMS [M+H]+ at m/z 356.1124. This side product increases with reaction time beyond 30 minutes and at temperatures exceeding 10°C, restricting DIC/Oxyma protocols to cryoactivation conditions and short (15 minute) pre-activation intervals.

Metal-Chelating Polymer Antioxidant Additives for Polyolefin Medical Packaging

Incorporation of the mercaptopyrrolidine benzoic acid into ethylene-vinyl acetate (EVA) copolymer matrices at loadings of 0.2–0.5 wt% creates radical-scavenging and metal-deactivating functionality in multi-layer blister packaging films for oxidation-sensitive pharmaceuticals. The compound is compounded into EVA (18 mol% VA content, melt flow index 2.5 g/10 min at 190°C/2.16 kg, ASTM D1238) on a co-rotating twin-screw extruder (L/D 40:1, screw diameter 25 mm) operating at zone temperatures 130–160°C and screw speed 200 rpm. The benzoic acid moiety coordinates trace metal residues—primarily titanium from Ziegler-Natta catalyst remnants and aluminum from slip agent stearates—forming stable complexes that suppress metal-catalyzed hydroperoxide decomposition in the melt phase and during product storage.

Regulatory standard: EU Regulation 10/2011 (Plastic Materials and Articles Intended to Come into Contact with Food), migration testing under simulant D2 (vegetable oil) at 40°C/10 days with specific migration limit for the additive provisionally evaluated at ≤0.01 mg/kg food simulant under EFSA positive list assessment protocol. Addition ratio: 0.2% for monolayer LDPE sealant layers; 0.5% for EVA tie-layer in aluminum foil laminates where metal-contact degradation is accelerated. Process: The additive is pre-dispersed as a 10% concentrate in EVA carrier via masterbatch let-down using a Buss MX-46 co-kneader (L/D 15:1) at 120–140°C with dispersive mixing pin configuration, then pelletized for subsequent dilution to target concentration on the primary film extrusion line. Terminal product: Cold-formable aluminum-plastic composite blister base film (total thickness 130–150 µm, OPA/Al/PVC laminate construction) for aspirin and ibuprofen solid dose packaging, where oxidative discoloration of the active ingredient is reduced by 40–60% versus unstabilized control as measured by CIELAB ΔE value after accelerated aging at 60°C/14 days.

The critical processing limitation encountered on cast-film lines involves the thiol’s volatility at processing temperatures. Thermogravimetric analysis (TGA, 10°C/min, N₂ atmosphere) reveals onset of mass loss at 172°C for the free thiol; the hydrochloride salt shifts this onset to 218°C as noted earlier. However, in the presence of EVA’s residual acetic acid (from VA monomer hydrolysis at processing temperatures above 180°C), the salt can undergo partial deprotonation, lowering the effective volatilization threshold by 15–20°C. This phenomenon is mitigated by incorporating a secondary zinc stearate acid scavenger (0.05 wt%) that neutralizes free acetic acid before it interacts with the mercaptopyrrolidine additive, thereby maintaining the thermal stability window during extrusion.

In the context of polymer stabilization, published data for this specific configuration is limited; however, the mercaptan anti-oxidant mechanism parallels established thioester chemistry (e.g., dilauryl thiodipropionate) operating through non-radical peroxide decomposition—the sulfur atom reduces hydroperoxides to alcohols via a two-electron pathway forming sulfoxide intermediates, subsequently oxidizing to sulfone under sustained oxidative stress. The rate constant for the initial sulfur oxidation step in the compound has been estimated by competitive kinetic experiments with cumene hydroperoxide in chlorobenzene at 75°C to be approximately 1.8 × 10⁻² L·mol⁻¹·s⁻¹, placing it intermediate between aryl and alkyl thiols in antioxidant efficacy.

Haze increase at the 0.5% loading results from partial immiscibility of the aromatic benzoic acid moiety at the EVA interface, detectable as diffuse scattering centers under SEM at 5000× magnification. This optical penalty restricts utility to opaque or metallized film structures, excluding applications for transparent blister cavities requiring haze ≤ 4% per pharmacopoeial monograph specifications for plastic containers (USP〈661.2〉).